TRZ 8MMAF
Alternative Names: Trastuzumab monomethyl auristatin F conjugate therapeutic - CHO Pharma/TE-Meds; TRZ-8MMAFLatest Information Update: 29 Apr 2024
At a glance
- Originator CHO Pharma; TE-Meds
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 19 Apr 2024 Preclinical trials in Breast cancer in Taiwan (Parenteral) prior to April 2024 (TE-Meds pipeline, April 2024)
- 19 Apr 2024 Pharmacodynamics data from a preclinical trial in Breast cancer released by TE-Meds (TE-Meds pipeline, April 2024)